Drug Profile
Alecmestencel-L
Alternative Names: Allogenic mesenchymal cell therapy - Minaris Regenerative MedicineLatest Information Update: 06 Jan 2021
Price :
$50
*
At a glance
- Originator Apceth
- Developer Apceth Biopharma
- Class Gene therapies; Mesenchymal stem cell therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Graft-versus-host disease; Inflammation
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Inflammation in Germany (Parenteral)
- 28 May 2018 No recent reports of development identified for clinical-Phase-Unknown development in Graft-versus-host-disease in Germany (Parenteral)
- 02 Apr 2015 Clinical trials in Graft-versus-host disease in Germany (Parenteral) before April 2015